Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BWAY vs BMRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BWAY Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)

BWAY Overall Winner 6-Pillar Tally: BWAY 5 – 0 BMRA (1 Tie) Matrix Metrics: BWAY 7 – 3 BMRA

As of Nov 16, 2026, Brainsway Ltd. (BWAY) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BWAY carries a Unified Composite Score of 33.8/100 (SELL) at $9.36 (17.9x Forward P/E, 12.5% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).

  • Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. BWAY 33.8/100 SELL), BWAY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.5% vs. -125.2% operating margin) and revenue trajectory (+35.4% vs. -8.3% YoY).
  • Technical & Structure Timing Caution: BWAY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BWAY vs BMRA
BWAY NASDAQ Head-to-Head Winner
Brainsway Ltd. American Depositary Shares
Surgical & Medical Instruments & Apparatus
$9.36
-7.47% 1D
Market Cap $412.6M
TTM Revenue $108M
Forward P/E 17.9x
Beta / 30D Vol 1.88β · 69% Vol
Unified Composite Score
33.8 / 100 SELL
Tech 34.0 Fund 45.0 Flow 50.0 Mom 49.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.0%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $11.13 · SMA50: $12.16
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96

6-Pillar Scorecard Institutional Category Breakdown (BWAY 5 – 0 BMRA)

Columns: Metric · BWAY · BMRA
1. Valuation Multiples BWAY
Forward P/E 17.9x N/M
Trailing P/E 42.7x N/M
PEG Ratio N/M N/M
EV / Revenue 3.8x 1.1x
2. Growth & Scale BWAY
Revenue Growth (YoY) +35.4% -8.3%
Earnings Growth (YoY) +59.8% +0.0%
TTM Revenue (USD) $108M $4.3M
Market Cap $412.6M $6.0M
3. Profitability & Quality BWAY
Gross Margin 75.3% 0.9%
Operating Margin 12.5% -125.2%
Net Profit Margin 15.6% -115.5%
Return on Equity (ROE) 12.8% -113.8%
4. Balance Sheet & Cash Flow BWAY
Cash Generation (TTM) $15M EBITDA -$3.2M
Cash Flow Margin 14.0% EBITDA Mgn -73.5%
Net Cash / Leverage $1.97 Book/Sh · 12.8% ROE $1.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 111.0% (77th %ile) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BWAY
OpEx & R&D Intensity 62.8% of Rev ($68M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BWAY (7) vs BMRA (3)
Institutional Metric BWAY BMRA Criterion Row Edge
Market Capitalization
Scale
$412.6M $6.0M Larger Scale BWAY
Trailing P/E Ratio
Valuation
42.7x N/M Lower Multiple BWAY
Forward P/E Ratio
Valuation
17.9x N/M Lower Multiple BWAY
Revenue Growth (YoY)
Growth
+35.4% -8.3% Higher Growth BWAY
Operating Margin (TTM)
Profitability
12.5% -125.2% Higher Margin BWAY
Net Profit Margin
Profitability
15.6% -115.5% Higher Margin BWAY
Return on Equity (ROE)
Capital Efficiency
12.8% -113.8% Higher ROE BWAY
52-Week Range Position
Momentum
1% ($9–$27) 4% ($1–$3) Stronger Trend BMRA
Beta / 30D Volatility
Risk Regime
1.88β · 69% Vol 0.67β · 62% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
33.8 / 100 (SELL) 44.5 / 100 (HOLD) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$108M $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.3% 0.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.8x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$15M EBITDA ($1.97 Book/Sh · 12.8% ROE) -$3.2M ($1.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BWAY +9.96 pp
BWAY: -18.23% · BMRA: -28.19%
3M Horizon BMRA +19.22 pp
BWAY: -36.19% · BMRA: -16.97%
6M Horizon BWAY +3.83 pp
BWAY: -37.13% · BMRA: -40.96%
1Y Horizon BWAY +5.29 pp
BWAY: -41.57% · BMRA: -46.86%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BWAY vs BMRA. Trailing 12-month operating profitability (BWAY 12.5% vs BMRA -125.2%) and valuation multiples (BWAY 17.9x vs BMRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BWAY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$108M
Gross Margin75.3%
Op. Margin12.5%
ROE / Fwd P/E12.8% · 17.9x
BMRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.3M
Gross Margin0.9%
Op. Margin-125.2%
ROE / Fwd P/E-113.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BWAY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 111.0%
IV Percentile 77th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BWAY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BWAY Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $412.6M market capitalization and 12.5% operating margin.
OpEx & R&D Reinvestment 62.8% of Rev ($68M)
90D Engineering Disclosures 0 Published
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BWAY vs BMRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Brainsway Ltd. (BWAY) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BWAY carries a Unified Composite Score of 33.8/100 (SELL) at $9.36 (17.9x Forward P/E, 12.5% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. BWAY 33.8/100 SELL), BWAY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.5% vs. -125.2% operating margin) and revenue trajectory (+35.4% vs. -8.3% YoY). Technical & Structure Timing Caution: BWAY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BWAY leads the Growth & Scale pillar: BWAY posts +35.4% YoY revenue growth and +59.8% YoY earnings growth on $108M TTM revenue (75.3% gross margin, 12.5% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). On trailing 12-month operating scale, BWAY generates $108M in USD-normalized revenue versus $4.3M for BMRA. In operating R&D and SG&A reinvestment, BWAY deploys 62.8% of Rev ($68M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.

BWAY screens cheaper on headline valuation multiples. BWAY trades at 17.9x Forward P/E, 42.7x Trailing P/E, N/M PEG, and 3.8x EV/Revenue (14.0% EBITDA margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BWAY (12.8% ROE) versus BMRA (-113.8% ROE) capital efficiency.

In options market volatility and institutional positioning, BWAY carries 111.0% implied volatility (77th %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.88β · 69% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.